Overnight Market report, page-70

relatlimab is the first lag-3 product to prove itself in PHIII, OK, whether it gets the go ahead from the FDA
in March remains to be seen but appears highly likely......
By then EFTI will be a considerable way into it's Head and Neck cancer in combination with keytruda trial which
immutep applied for and was granted FDA fast track trial status a few months back.....
Given minimal side effect issues and heavy unmet need for H& N Cancer treatment things may work out favourably
for EFTI with possibly a flow on effect for NSCLC...Gonna get very interesting and it's not that far away..